Otero Mateo, MarcEstrany Jr, FrancescArcas Márquez, SabrinaMoya Borrego, LauraCastellano, GiancarloCastany Roma, MiquelAlemany Bonastre, RamonFillat i Fonts, Cristina2025-07-172025-07-172025-03-011525-0016https://hdl.handle.net/2445/222340Oncolytic adenoviral therapy is a promising approach for pancreatic cancer treatment. However, the limited capacity of murine cells to produce infectious viral progeny precludes the full evaluation of the virotherapy in a suitable immunocompetent mouse model. Here, we report that the murine KPC-I cell line, established from pancreatic tumors developed in to adenoviral replication and generates a progeny of infective virions similar to those from infected human A549 cells. A comparative study with the semipermissive murine CMT64.6 cells reveals that adenoviral infection of KPC-I cells substantially increases the release of infective particles, with a correlating enhanced susceptibility to adenovirus-induced autophagy. Remarkably, systemic delivery of the oncolytic adenovirus AdNuPARE1A in athymic mice bearing KPC-I tumors results in significant inhibition of tumor growth. Moreover, KPC-I tumors in immunocompetent mice with intratumoral administration of AdNuPARE1A or ICOVIR15kDelE3 display significant antitumoral effects, with evidence of adenoviral replication. Collectively, our data show that KPC-I cells are permissive to human oncolytic adenovirus replication, rendering KPC-I syngeneic tumors an interesting model to evaluate the multifaceted antitumor activities of oncolytic adenovirus.12 p.application/pdfengcc-by-nc-nd (c) Otero Mateo, Marc et al., 2025http://creativecommons.org/licenses/by-nc-nd/3.0/es/Càncer de pàncreesTerapèuticaPancreas cancerTherapeuticsinfo:eu-repo/semantics/article2025-05-16info:eu-repo/semantics/openAccess39877727